Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
146 participants
INTERVENTIONAL
2022-01-01
2023-05-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The key question(s) it aims to answer are:
\[Does the use of fibrinogen concentrate reduce bleeding in PAS patients?\] Patients who had a cesarean section with a pre-diagnosis of PAS were analyzed retrospectively. The choice of anesthesia applied to the patients and the relationship between the use of blood products and bleeding were evaluated.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Reducing Blood Loss During Cesarean Hysterectomy for Placenta Accreta Spectrum
NCT03570710
Extra-abdominal Removal of Placenta During CS
NCT02101450
The Value of Tranxemic Acid to Reduce Intraoperative Blood Loss During Elective Cesarean Sections in High Risk Women
NCT03820206
Comparing Tranexamic Acid Versus Ecbolics in Preventing Hemorrhage During and After Cesarean Section
NCT06060327
The Impact of Mechanical Methods on the Postpartum Haemorrhage Prophylaxis During Caesarean Section
NCT05948436
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
examined. were randomized into 2 groups, 53 patients in each group: group1: GNF : the group without fibrinogen concentrate
Group 2: GF: the group with fibrinogen concentrate
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
grup 1: the group without fibrinogen concentrate (GNF)
grup 1: the group without fibrinogen concentrate (GNF)
the group without fibrinogen concentrate (GNF) , the group with fibrinogen concentrate (GF)
the group without fibrinogen concentrate (GNF, ) the group with fibrinogen concentrate (GF)
Grup 2: the group with fibrinogen concentrate
Grup 2: the group with fibrinogen concentrate
the group without fibrinogen concentrate (GNF) , the group with fibrinogen concentrate (GF)
the group without fibrinogen concentrate (GNF, ) the group with fibrinogen concentrate (GF)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
the group without fibrinogen concentrate (GNF) , the group with fibrinogen concentrate (GF)
the group without fibrinogen concentrate (GNF, ) the group with fibrinogen concentrate (GF)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* \>34 weeks of pregnancy
* Those with normal renal functions
Exclusion Criteria
* Those with \<34 weeks of gestation
* Pregnant women with missing data
20 Years
50 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bakirkoy Dr. Sadi Konuk Research and Training Hospital
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Duygu Akyol
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Duygu Akyol
Role: PRINCIPAL_INVESTIGATOR
Başakşehir Çam & Sakura City Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Duygu Akyol
Istanbul, Basaksehir, Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Morlando M, Collins S. Placenta Accreta Spectrum Disorders: Challenges, Risks, and Management Strategies. Int J Womens Health. 2020 Nov 10;12:1033-1045. doi: 10.2147/IJWH.S224191. eCollection 2020.
Shainker S, Shamshirsaz A, Haviland M, O'Brien K, Redhunt A, Bateni Z, Moaddab A, Fox K, Hui SK, Belfort M, Dildy G, Hacker M. Utilization and outcomes of massive transfusion protocols in women with and without invasive placentation. J Matern Fetal Neonatal Med. 2020 Nov;33(21):3614-3618. doi: 10.1080/14767058.2019.1581168. Epub 2019 Mar 1.
DeSimone RA, Leung WK, Schwartz J. Transfusion Medicine in a Multidisciplinary Approach to Morbidly Adherent Placenta: Preparing for and Preventing the Worst. Transfus Med Rev. 2018 Oct;32(4):244-248. doi: 10.1016/j.tmrv.2018.05.007. Epub 2018 Jun 27.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.